Rebound of macular edema after intravitreal bevacizumab therapy in eyes with macular edema secondary to branch retinal vein occlusion

Keyphrases

• Macular Edema 100%
• Bevacizumab Therapy 100%
• Branch Retinal Vein Occlusion 100%
• Intravitreal Bevacizumab 100%
• Foveal Thickness 45%
• Symptom Onset 27%
• Subgroup Analysis 18%
• Pretreatment Factors 18%
• Logistic Regression Analysis 9%
• Treatment Initiation 9%
• Short Intervals 9%
• Thickness Ratio 9%
• Fovea 9%

Medicine and Dentistry

• Bevacizumab 100%
• Rebound 100%
• Branch Retinal Vein Occlusion 100%
• Macular Edema 100%
• Symptom 27%
• Subgroup Analysis 18%
• Recurrent Disease 9%
• Multivariate Logistic Regression Analysis 9%
• Rovazolac 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Bevacizumab 100%
• Macular Edema 100%
• Branch Retinal Vein Occlusion 100%
• Symptom 27%
• Recurrent Disease 9%
• Rovazolac 9%